Similar articles

• Oral anticoagulant use around the time of atrial fibrillation ablation: a review of the current evidence of individual oral anticoagulant use for periprocedural atrial fibrillation ablation thromboembolic prophylaxis.

  Garton AB, Dudzinski J, Kowey PR. Garton AB, et al. J Cardiovasc Electrophysiol. 2014 Dec;25(12):1411-8. doi: 10.1111/jce.12546. Epub 2014 Oct 10. J Cardiovasc Electrophysiol. 2014. PMID: 25216104 Review.
• Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.

  Abraham NS, Singh S, Alexander GC, Heien H, Haas LR, Crown W, Shah ND. Abraham NS, et al. BMJ. 2015 Apr 24;350:h1857. doi: 10.1136/bmj.h1857. BMJ. 2015. PMID: 25910928 Free PMC article.
• Novel oral anticoagulants in atrial fibrillation: which novel oral anticoagulant for which patient?

  Prisco D, Cenci C, Silvestri E, Ciucciarelli L, Di Minno G. Prisco D, et al. J Cardiovasc Med (Hagerstown). 2015 Jul;16(7):512-9. doi: 10.2459/JCM.0000000000000262. J Cardiovasc Med (Hagerstown). 2015. PMID: 25798903 Review.
• Population-based evaluation of the management of antithrombotic therapy for atrial fibrillation.

  Anderson DR, Gardner MJ, Putnam W, Jassal D, Brownell B, Flowerdew G, Nagpal S, Thompson K, Cox JL. Anderson DR, et al. Can J Cardiol. 2005 Mar;21(3):257-66. Can J Cardiol. 2005. PMID: 15776115
• Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.

  Potpara TS, Polovina MM, Licina MM, Stojanovic RM, Prostran MS, Lip GY. Potpara TS, et al. Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7. Adv Ther. 2012. PMID: 22684583 Review.